Market Insights
Asthma is a chronic respiratory disease that causes inflammation and narrowing of the airways. COPD (Chronic Obstructive Pulmonary Disease) is a lung disease that makes breathing difficult, including chronic bronchitis and emphysema, and that gets worse with time. COPD is one of the leading causes of mortality and morbidity worldwide, with a prevalence rate of 5–13%.
Increases in smoking rates and air population are directly proportional to prevalence rates, particularly in developing countries. New pharmacologic options for asthma and COPD have been investigated by focusing on specific biological mechanisms and understanding the pathogenesis of these diseases. As a result, the introduction of new drugs may provide better treatment options. The generic entry of a drug might affect the market, slowing its growth of the market. With key players innovating novel combination therapies and using biologics, personalized treatment would drive the asthma and COPD drug market.
The report titled “Asthma and COPD Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into overall asthma and COPD drug market, along with the market size and estimates for the duration of 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on types of drugs and different geographies. The drug types studied for analyzing the overall global asthma and COPD drugs market are majorly segmented into anti-inflammatory drugs, bronchodilator monotherapy, and combination drugs. Anti-inflammatory drugs include corticosteroids, anti-leukotrienes, and monoclonal antibodies. Bronchodilator monotherapy includes short-acting beta2-agonists (SABAs) and long-acting beta2-agonists (LABAs), and anticholinergics.
Geographically, global asthma and COPD drugs market is studied for the following regional markets:
-
-
- North America
- Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
- Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in global asthma and COPD drugs market.
Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the competitive scenario of global asthma and COPD drugs market. This report concludes with a company profiles section that highlights major information about the key players engaged in global asthma and COPD drugs market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.
Based on the type of drug, global asthma and COPD market is segmented as follows:
-
-
- Anti-inflammatory drugs
- Corticosteroids
- Anti-Leukotrienes
- Monoclonal antibodies
- Bronchodilator monotherapy
- Short-acting beta2-agonists (SABAs)
- Long-acting beta2-agonists (LABAs)
- Anticholinergics
- Combination drugs
Currently, treatment available for asthma and COPD includes anti-inflammatory drugs, bronchodilator monotherapy, and combination therapy, of which combination therapy dominates the market. The most preferred combination for treatment is a long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination that includes Symbicort (AstraZeneca) and Advair (GlaxoSmithKline).
The combination is most preferred due to its better efficacy, convenient delivery mechanism, and decreased side effects. Singulair, Seretide, and Spiriva have commonly used medications for the treatment of asthma and COPD in the US and Europe. Further, an increase in the use of corticosteroids in combination with bronchodilators would drive the treatment market for asthma and COPD. Recent treatments such as combination products once daily and monoclonal antibodies will create new growth opportunities for the market.
There are many studies in various stages of development in the pipeline. Pharmaceutical companies have been investing heavily in the research and development of new biologics with the help of biotechnology, which would create immense market opportunities for the sustainable development of asthma and COPD markets. The only biologic currently available for the treatment of asthma is Novartis’ immunoglobulin E (IgE) inhibitor Xolair (omalizumab). Benralizumab Astrazenca’s first biologic is expected to enter the market next year, which would create a new wave for the use of biologics for the treatment of asthma.
For the purpose of this study, global asthma and COPD market are geographically categorized into:
-
-
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
At present, North America dominates global asthma and COPD market, followed by the European market. The major drivers for the North American market are the rising prevalence of asthma and COPD, technological advancements in treatment, a delay in the influx of generics, and a strong pipeline of novel therapies. The prevalence of asthma and COPD is increasing in developed countries due to factors such as smoking, sedentary lifestyles, obesity, genetic factors, etc.
The rise in demand for treatment and the high cost of treatment also contribute to market growth. Asia-Pacific is anticipated to be the fastest-growing market during the forecast period. In emerging countries such as China, India, and others, there is an increase in the incidences of asthma and other respiratory diseases due to rising pollution, urbanization, sedentary lifestyles, and prolonged life expectancy.
